Bavarian Nordic A/S – Interim Report for the period 1 January to 31 March 2011

Not for release, publication or distribution in the United States, Canada, Australia or Japan

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Bavarian Nordic A/S (the "Securities") in the United States or in any other jurisdiction. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of the Offering in the United States or in any jurisdiction outside Denmark and the United Kingdom, and does not intend to conduct a public offering of the Securities in the United States or in any other jurisdiction outside Denmark and the United Kingdom. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.

This announcement is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors, as that term is defined in the Prospectus Directive, that are also (i) "investment professionals" falling within Article 19(5) of the Financial Service and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) "high net worth entities" and other persons to whom it may lawfully be communicated, falling within the meaning of Article 49(2)(a) to (d) of the Order (all such persons being "relevant persons"). The securities of Bavarian Nordic A/S (the "Securities") are only available to relevant persons and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its content.

Click here for full report in PDF

Kvistgaard, Denmark, May 31, 2011 - Bavarian Nordic A/S (OMX: BAVA) today publishes its first quarter 2011 results. Bavarian Nordic generated revenue of DKK 29 million and recorded a loss before tax of DKK 135 million. As of 31 March 2011 the cash preparedness was DKK 326 million, including credit lines of DKK 112 million. After the successful completion of a rights issue in May 2011, the cash preparedness has been significantly strengthened and amounts to approximately DKK 825 million by end of May. The company maintains its full-year expectations with revenues in the level of DKK 500 million, and a pre-tax loss in the level of DKK 350 million. The cash preparedness at year-end is expected to be in the level of DKK 525 million.

Anders Hedegaard, President & CEO commented on the interim report: "Since we announced our new development strategy for PROSTVAC® there has been much focus on Bavarian Nordic and we are therefore delighted that the successful rights issue last week has enabled us to pursue the independent development of PROSTVAC® and thus initiate the Phase 3 trial in the second half of 2011 as planned. At the same time we have secured both the progress of the project, as well as a strong position in the further discussions with potential partners by maintaining the value of the project in the company. We have also witnessed important events in our Infectious Disease division, especially with the expansion of the contract for freeze-dried IMVAMUNE®, which further strengthens the ties with the U.S. Government, leading to potential new, future contracts."

Highlights from the period 

• Marketing authorization application for IMVAMUNE® submitted in Canada
  In March, Bavarian Nordic submitted a marketing authorization application in Canada for IMVAMUNE®. If found acceptable by Health Canada following a standard NDS review time of approximately one year, IMVAMUNE® will be indicated for active immunization against smallpox in the general population of 18 years and older.
  
   
• New Phase 2 study comparing PROSTVAC® and chemotherapy versus chemotherapy
  A new multicenter, randomized Phase 2 study of 144 patients with metastatic castration-resistant prostate cancer (mCRPC) was initiated in February 2011. The study will compare PROSTVAC® followed by docetaxel (chemotherapy) versus docetaxel alone. Currently, PROSTVAC® is being investigated alone or as combination therapy in six ongoing clinical Phase 1 and Phase 2 studies in a total of more than 370 patients in different disease settings.  

Contact:

Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64